Molecure 미래 성장
Future 기준 확인 5/6
Molecure is forecast to grow earnings and revenue by 64.7% and 108.5% per annum respectively.
주요 정보
64.7%
수익 성장률
n/a
EPS 성장률
| Pharmaceuticals 수익 성장 | 15.4% |
| 매출 성장률 | 108.5% |
| 향후 자기자본 수익률 | n/a |
| 애널리스트 커버리지 | Low |
| 마지막 업데이트 | 16 Oct 2024 |
최근 미래 성장 업데이트
Recent updates
Is Molecure (WSE:MOC) In A Good Position To Deliver On Growth Plans?
Aug 20
Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?
Apr 20We're Keeping An Eye On Molecure's (WSE:MOC) Cash Burn Rate
Dec 01Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?
Jul 07Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth
Mar 10Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth
Aug 16OncoArendi Therapeutics' (WSE:OAT) Earnings Are Weaker Than They Seem
Nov 04Is OncoArendi Therapeutics S.A.'s (WSE:OAT) Shareholder Ownership Skewed Towards Insiders?
Feb 24Will OncoArendi Therapeutics (WSE:OAT) Spend Its Cash Wisely?
Jan 02수익 및 매출 성장 예측
| 날짜 | 수익 | 수익 | 잉여 현금 흐름 | 작전 현금 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2026 | 79 | 15 | N/A | 47 | 1 |
| 12/31/2025 | 49 | -36 | N/A | 25 | 1 |
| 12/31/2024 | 4 | -27 | N/A | -25 | 1 |
| 9/30/2024 | 2 | -31 | -61 | -33 | N/A |
| 6/30/2024 | 2 | -30 | -67 | -29 | N/A |
| 3/31/2024 | 2 | -29 | -55 | -16 | N/A |
| 12/31/2023 | 4 | -28 | -57 | -23 | N/A |
| 9/30/2023 | 9 | -45 | -53 | -40 | N/A |
| 6/30/2023 | 8 | -42 | -41 | -34 | N/A |
| 3/31/2023 | 8 | -39 | -48 | -39 | N/A |
| 12/31/2022 | 8 | -36 | -44 | -34 | N/A |
| 9/30/2022 | 2 | -16 | -36 | -8 | N/A |
| 6/30/2022 | 2 | -16 | -38 | -14 | N/A |
| 3/31/2022 | 2 | -15 | -37 | -15 | N/A |
| 12/31/2021 | 1 | -14 | -32 | -13 | N/A |
| 9/30/2021 | 124 | 63 | 63 | 47 | N/A |
| 6/30/2021 | 124 | 64 | 62 | 47 | N/A |
| 3/31/2021 | 125 | 67 | 67 | 56 | N/A |
| 12/31/2020 | 125 | 68 | 66 | 57 | N/A |
| 9/30/2020 | 2 | -3 | -31 | -2 | N/A |
| 6/30/2020 | 2 | -3 | -32 | -2 | N/A |
| 3/31/2020 | 2 | -4 | -38 | -6 | N/A |
| 12/31/2019 | 2 | -4 | -42 | -7 | N/A |
| 9/30/2019 | 2 | -5 | -43 | -4 | N/A |
| 6/30/2019 | 2 | -5 | -41 | -6 | N/A |
| 3/31/2019 | 1 | -5 | -36 | -4 | N/A |
| 12/31/2018 | 1 | -4 | -32 | -5 | N/A |
| 9/30/2018 | 1 | -4 | -28 | -5 | N/A |
| 6/30/2018 | 2 | -4 | N/A | -2 | N/A |
| 3/31/2018 | 2 | -2 | N/A | -2 | N/A |
| 12/31/2017 | 1 | -2 | N/A | -1 | N/A |
| 9/30/2017 | 1 | -3 | N/A | -5 | N/A |
| 6/30/2017 | 1 | -3 | N/A | -4 | N/A |
| 3/31/2017 | 1 | -3 | N/A | -3 | N/A |
| 12/31/2016 | 1 | -2 | N/A | -1 | N/A |
| 12/31/2015 | 1 | -1 | N/A | -2 | N/A |
애널리스트 미래 성장 예측
수입 대 저축률: MOC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.9%).
수익 vs 시장: MOC is forecast to become profitable over the next 3 years, which is considered above average market growth.
고성장 수익: MOC is expected to become profitable in the next 3 years.
수익 대 시장: MOC's revenue (108.5% per year) is forecast to grow faster than the Polish market (4.3% per year).
고성장 수익: MOC's revenue (108.5% per year) is forecast to grow faster than 20% per year.
주당 순이익 성장 예측
미래 자기자본 수익률
미래 ROE: Insufficient data to determine if MOC's Return on Equity is forecast to be high in 3 years time